Digipharm aims to leverage innovative blockchain technology to address patient access barriers and innovative pricing, reduce costs for all stakeholders, and bypass infrastructure constraints to drive value enhancement, drive innovation and accelerate transformation into personal healthcare.
Health systems are often required to make difficult decisions about whether to reimburse the cost of pharmacological therapy and provide access to patients while considering their limited resources. The innovative pricing approach has the ability to overcome the challenges faced by the health care system when assessing new drug funding, to enable the implementation of a 'flexible' pricing scheme to assess the price of care in relation to the benefits it provides. Unfortunately, health care systems around the world do not have the relevant infrastructure to track and implement innovative pricing models such as value-based pricing agreements, and are therefore reluctant to adopt such innovative policies. This resulted in rejected new pharmacologic therapy for the most needy patients, a missed opportunity to reduce the economic burden and long-term disease of the health system, and a barrier to reimbursement for producers.
Health digitization is a key element for improving patient outcomes, their quality of life and reducing the heavy burden on health systems worldwide. The health care industry underwent a paradigm shift to value-based care because of growing demand, an aging population, chronic illness and unsustainable levels of health spending. The healthcare system is transitioning towards value-based care to prevent rationing of services and increasing costs for patients and payers without sacrificing quality of care. The provision of health care from a value-based perspective is based on the underlying goal of producing optimal patient outcomes relative to monetary outlays.
The health care system progresses from the cost recovery model for cost reimbursement to a 'cost-for-performance' system associated with patient outcomes. By 2020, it is estimated that 75% of commercial payments for high-cost therapies will be implemented in accordance with value-based agreements ( Deloitte 2015 ). The provision of value-based health services will be a fairer system that provides incentives for pharmaceutical companies to develop innovative and rewarded medicines, while not inhibiting access to these drugs to the patients who need them most. Value-based pricing agreements are one of a series of options in a range of innovative pricing solutions. Ultimately, this solution is set with the goal of providing access to the right medicine, at the right time to the patient and at the right cost for the health care system and the manufacturer.
Digipharm is committed to deliver value-based health solutions beyond innovative prices and market access solutions for pharmaceutical products. The architecture embedded in the Reimburse platform will further promote the advancement of broader health ecosystems into economically viable economic value-based practices. Development of an alternative payment system such as a bundled payment model using intelligent contract technology, and focuses on the implementation of a standard results reporting framework with the help of industry thinking leaders
will play a key role in augmenting the mass adoption of value-based health services delivery. The distributed ledger technology combined with scalable integration solutions also provides intelligent solutions for embedded inefficiency and waste that are typically associated with health-related data collection, claims of fragmented adjudication and collaboration between health care providers and payers. Reimburse platform retrieval will support the incorporation of health care delivery between fragmented and fragmented institutions to manage care for different patient groups while serving as a common platform for addressing allocative efficiency issues using methods such as time driven activity based costing ( TDABC ).
Our vision
To pioneer the delivery of sustainable and value-based health services, the generation of innovative evidence and patient empowerment across the health care industry.
Problem
- Barriers to innovative pricing and 'paying for performance
Healthcare systems are often required to make their own limited resources. Innovative pricing approaches have the ability to overcome the challenges faced by healthcare systems when assessing the funding of new drugs, to enable the implementation of 'flexible' pricing schemes to assess the price of treatment in relation to the benefits it delivers. Unfortunately, healthcare systems around the world lack the relevant infrastructure to track and implement innovative pricing agreements, and so reluctant to adopt such innovative policies. This results in novel pharmacological therapies being the burden on health systems and a barrier to reimbursement for manufacturers.
- Limitations of conventional real world evidence
Real world evidence (RWE) is playing an increasingly influential role in informing decision making within the healthcare industry and is crucial to informing value-based healthcare. Yet the delay of RWE outputs, the expenses of data access and the current methods of data collection. The lack of easily accessible and comprehensive RWE currently prevents stakeholders in healthcare to evaluate the real time performance and value provided by therapy in real life clinical practice as part of a value-based healthcare delivery system.
Solutions
- Reimburse
The Reimburse platform harnesses the benefits of automated 'smart contracts' and blockchain technology; facilitating the application of truly dynamic innovative pricing solutions between healthcare systems and manufacturers, in a secure and compliant fashion with minimal administrative burden. Use of the Reimburse platform will expedite integration, coordination and delivery of patient centric healthcare systems with a focus on improving patient outcomes while accelerating 'payment for value' mechanisms between payers and manufacturers using neutrally-enforceable agreements in peer to peer fashion.
- Insights
The Insights platform will extract anonymised patient level data from the Reimburse platform and health information systems to the world's first 'live' RWE database. Insights will provide a progressive transformation towards value-based healthcare delivery systems. The development of a 'live' evidence repository will allow the integration of knowledge back into the delivery system in real time to facilitate decision making, drug development and health related research. Patients will be incentivised to contribute their health information to the platform and will gain access to health information that is currently unattainable.
Market potential
The potential of the Reimburse platform is remarkable because it will be able to support smart contracts for new and existing treatments as healthcare systems around the world continue to drive the transformation to value-based services. Cancer drugs have been the most studied in recent years and are driving growth in pharmaceutical drug pipeline. This is a big challenge because these drugs often carry high price tags that contribute to the benefits they bring. The cost of patented cancer drugs in the US alone has risen 5-10 times since the turn of the century, with median drug treatment costs around $ 100,000 per year with patients who are generally responsible for 20-30% as collective payments ( Kantarijan et al 2014 ). High prices for innovative therapies that may or may not work may result in patients refusing treatment or choosing a treatment plan that is less than optimal due to financial difficulties they may encounter ( Zafar et al 2013 ). In the United States, the leading payers of UnitedHealth, Aetna and Anthem are close to achieving their current target of 50% of total annual health care spending through value-based care and simple 'pay for performance' agreements ( Forbes 2017 ). Aetna strives to lead the industry with a 75% target value-based spending model by 2020, as they hope to build on their current initiatives to improve quality care and lower costs at the same time ( Forbes 2017; Bach & Pearson 2015 ).
Insight Platform
The Insights Platform will extract anonymized patient-level data from the Reimburse platform and electronic patient records to real, real-world ( real ) real world ( RWE ) databases, accessible to real-time subscribers ( Figure 5 ). Uniform input and standards for smart contracts packed in Reimburse platform and Digipharms' order integration integration architecture for health information information systems address immediately some limitations are observed with RWD collection and generation of conventional databases, thereby speeding up time for the availability of consistent and 'ready-to-use' RWE output. Additional health-related data such as genome data will also be linked to the Insight platform in partnership with the industry's leading evidence providers, to create an unparalleled health data market in preparation for a value-based future and based on health data. Use
cryptographically encrypted blockchain technology also eliminates all patient privacy and data security concerns affecting current RWE generation systems. No live 'RWE' database is currently available.
CHARACTERISTIC OF DPH TOKEN
- DPH Supply : 100,000,000 Fixed (ERC-20)
- Code Ticker : DPH
- Decimal Place : 18
- Token Price : 1.00 USD
DPH TOKEN SALE
- PRE - SALE : 15,000,000 DPH
- Base Price : 1.0 USD
- Pre-Sales Length : 4 Weeks
- Pre-Discount Sales : 35%
KEY SALES 50,000,000 DPH
- Week 1 : 25% is limited to 25 million tokens
- Week 2 : 15% closed at 15 million tokens
- Week 3 : 10% is limited to 10 million tokens
- Week 4 : 1.00 USD
Any unsold token will be burned.
DIGIPHARM TEAM
- Ahmed Abdulla - Founder / CEO
- Girisha Fernando - Co-Founder / COO
- Zach Daniels - CTO
- Ralf Gerteis - Commercial Strategy
- Alexander Sverdlov - Cybersecurity Strategy
- Meredith Darden - Digital Marketing Leader
- Alexey Popov - Web Development
- Michael Gubert - UI / UX Design
- Leon Rebolledo - Main Architect
- Rolf Günter - Legal Counsel
- Bobby Kaura - Business Development
- Dr. Mohamed Abdulla - Clinical Transformation
- Dr. Hasham Al-Meshhedani - Patient Involvement
- Ali Al-Sudani - Clinical Pharmacist
- Dr. Rami Radwan - Clinical Relation
- Peter Sandbach - Director of Communications
- Debra De Silva-Sun - HEOR & Analyst Appraisal
- Marko Granic - Graphic Designer
ADVISER DIGIPHARM
- Sven Möller - ICO Adviser. Swisscom Blockchain AG
- Kamal Youssefi - Corporate Advisory Blockchain. Swisscom Blockchain AG
- Waldemar Scherer - Life Sciences Blockchain Advisor. Swisscom Blockchain AG
- Sam Mantle - Technology Advisor for Life & Health Sciences. Luxoft
- Daniel Heller - PR Adviser. Partner, Farner Consulting AG
- Claudio Staub - Co-Head Startup Communications. Farner Consulting AG
- Anas Aman - Quality and Testing. IBM
- Lloyd Jefferies - CRM Advisor. KPMG
- Per-Olof Thuresson - Health Economist. Roche
- Fadi Chehadah - Health Economist. NICE UK
Digipharm uses blockchain technology on their platform to enable and promote the distribution of universally available, safe and transparent medical data infrastructure. Maintenance and utility of this platform will provide the joint protection of advanced security measures that comply with the information management protocol. Digipharm strongly believes in strengthening patients with full ownership and custody of their personal data. This is the desired level of security in today's health care industry.
For more details about our ICO you can also visit our website address below :
- Website : https://www.digipharm.ch/
- Technical document : https://digipharm.ch/docs/DigipharmWP.pdf
- Twitter : https://twitter.com/DigipharmTeam
- Facebook : https://www.facebook.com/digipharmteam/
- Telegram : https://t.me/joinchat/ExOHxk-TuOplQDbBWXaLaQ
Author Article : Lelaapril2004
ETH : 0x0bF3d407cF25D98886d707d2355E7Cd00191c142
Tidak ada komentar:
Posting Komentar